Synergistic effect of alectinib and everolimus on anaplastic large cell lymphoma cells via ALK-mTOR pathway inhibition
ALK와 mTOR 억제제인 alectinib와 everolimus 복합요법의 미분화 대세포 림프종 세포에 대한 증식억제 상승효과 분석

Cited 0 time in webofscience Cited 0 time in scopus
의과대학 협동과정 종양생물학전공
Issue Date
서울대학교 대학원
학위논문 (석사)-- 서울대학교 대학원 : 의과대학 협동과정 종양생물학전공, 2018. 8. 윤성수.
The purpose of this study was to investigate the synergistic effect of combination treatment of two drugs on ALK-positive cancer cells. The combination treat resulted in synergistic effect in Karpas299 cells but not in SU-DHL-1 cells. Viability of Karpas299 cell was decreased to 26.4% (p<0.001) by combination treatment of alectinib and everolimus compared with the single drug treated groups (alectinib: 59.5%, everolimus: 51.6%), and the value of Combination Index (CI) indicating synergism was 0.316. Moreover, combination treatment in Karpas299 augmented ALK-mTOR de-phosphorylation, and cleavage of poly ADP ribose polymerase (PARP) molecules. Combination treatment significantly increased the numbers of Karpas299 cells arrested at subG1 (everolimus: p= 0.0096), and G0/G1 (alectinib: p= 0.0018
everolimus: 0.0013). We further investigated the biological differences between Karpas299 and SU-DHL-1, the expression pattern of ALK isoforms (ALK-201 and 203) was different between the two cell lines. Overall, Combination treatment with alectinib and everolimus synergistically reduced cell survival, augmented inhibition of mTOR signaling, and increased cell cycle arrest in Karpas299 but not in SU-DHL1 cells. This set of results can suggest that the possibility of a novel combination treatment for ALK-positive lymphoma patients. It also provides an approach to developing new therapies.
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Cancer Biology (협동과정-종양생물학전공)Theses (Master's Degree_협동과정-종양생물학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.